Clinical trial · no report yet · Phase 2
ReVenG
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- NCT04895436 ↗
- Recruiting
- AbbVie
- 24 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 12 | |
| Podcasts | 9 | |
| X threads | 2 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- Venetoclax; Obinutuzumab
- Arms
- Cohort 1 - venetoclax + obinutuzumab · Experimental
- Cohort 2 - venetoclax + obinutuzumab · Experimental
- Enrollment
- 75 (estimated)
- Primary outcomes
- Overall response (OR) in Cohort 1 after end of combination treatment
- Sponsor
- AbbVie with F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute
- Start
- Mar 28, 2022
- Primary completion
- Nov 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04895436 · updated Feb 9, 2026
Publications
linked from the registry- Castonguay M, Anderson MA, Thompson P, Seymour JF. Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective. Blood Adv. 2026 May 26;10(10):3357-3366. doi: 10.1182/bloodadvances.2026019871. PubMed 41843779